Sort
50,496 grants matching “lung cancer”
Dayton Clinical Oncology Program
$1,013,114Howard M Gross · Dayton Clinical Oncology Program · U10 · FY2012 · CA
Molecular Analysis Of Cell Cycle Control During Carcinogenesis
$1,012,791Richard S Paules · National Institute Of Environmental Health Sciences · Z01 · FY2008 · ES
Wide-Field Quantitative Fluorescence Imaging System
$1,012,560David W Roberts · Insight Surgical Technologies Inc. · R44 · FY2022 · CA
Biochemical Analysis of Multidrug Resistance-linked Transport Proteins
$1,012,470Suresh Ambudkar · Division Of Basic Sciences - Nci · ZIA · FY2010 · CA
Preclinical development of AlaTIMP-2 as an cancer therapeutic
$1,012,438William Stetler-Stevenson · Division Of Basic Sciences - Nci · ZIA · FY2009 · CA
Preclinical Characterization of Drugs in Mouse Model of Lung Cancer
$1,012,184Terry Van Dyke · Division Of Basic Sciences - Nci · ZIA · FY2014 · CA
Genetic Epidemiology of Cancer
$1,011,986Joan E. Bailey-Wilson · National Human Genome Research Institute · ZIA · FY2020 · HG
Red Cell Biology
$1,011,971David M. Bodine · National Human Genome Research Institute · ZIA · FY2021 · HG
Exisulind for Chemoprevention of Lung Cancer
$1,011,860Gerold Bepler · H. Lee Moffitt Cancer Ctr & Res Inst · U01 · FY2006 · CA
Non-Clinical Pharmacology of CX-01
$1,011,743Galina Vid · Ceramedix Holding, Llc · R44 · FY2023 · AI
Humanization, Production, and PK/PD Characterization of anti-TIP1 antibody against Non-Small Cell Lung Cancer
$1,011,611Sapna Deore · Medical Guidance Systems, Llc · R44 · FY2019 · CA
Liver Cancer Disparities in Alaska Native and American Indian People
$1,011,489George Ioannou · University Of Washington · P20 · FY2021 · CA
Development of TIMP-2 derivatives or strategies as biologic therapies for cancer
$1,011,465William Stetler-Stevenson · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA
Breast, Colorectal, and Ovary Cancer Clinical Validation Center
$1,011,430Christopher I Li · Fred Hutchinson Cancer Research Center · U01 · FY2016 · CA
Phase I Clinical Testing of a First-in-Class Therapy against Metastatic Cancer
$1,011,207Zdravka O. Medarova · Transcode Therapeutics, Inc. · R44 · FY2024 · CA
Vanderbilt-Emory-Cornell-Duke Consortium for Global Health Fellows (VECDor)
$1,011,000Sten H Vermund · Vanderbilt University · R25 · FY2014 · TW
1/3 Morehouse School of Medicine/Tuskegee University/University of Alabama at Birmingham O'Neal Comprehensive Cancer Center Partnership
$1,010,535Brian M. Rivers · Morehouse School Of Medicine · U54 · FY2024 · CA
Epidemiology and Natural History of Cancer-Associated Viruses
$1,010,365Sam M Mbulaiteye · Division Of Cancer Epidemiology And Genetics · ZIA · FY2017 · CA
GENOMIC AND FUNCTIONAL CHARACTERIZATION OF CHEMORESISTANCE IN SMALL CELL LUNG CANCER
$1,009,750The Geneva Foundation · · FY2025 · Defense Health Agency
Behavioral Science Core
$1,009,613Alan S Wayne · Division Of Basic Sciences - Nci · ZIC · FY2011 · CA
Monitoring Immunotherapy Response via Gene Silencing Landscapes in Cell-Free DNA
$1,009,228Michael T Barrett · Binary Genomics, Inc. · R44 · FY2025 · CA
LUNG CANCER CHEMOPREVENTION WITH CELECOXIB IN EX-SMOKERS
$1,009,078University Of California Los Angeles · U01 · FY2002 · CA
Novel therapeutic development for small cell lung cancer
$1,008,900Charles M Rudin · Sloan-Kettering Inst Can Research · R35 · FY2024 · CA
Shanghai Men's Health Study
$1,008,853Xiao-Ou Shu · Vanderbilt University · UM1 · FY2014 · CA
Identification of epithelial tumor susceptibility genes
$1,008,772Allan Balmain · University Of California, San Francisco · U01 · FY2007 · CA